BIOMAT Database Logo BIOMAT Database Logo

Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). 1997

L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Scott and White Memorial Hospital, Temple, Texas 76508, U.S.A.

OBJECTIVE Despite improved event-free survival of older children with acute lymphocytic leukemia (ALL), infants <1 year of age continue to have a very poor prognosis. A new therapy designed specifically for infants with ALL was initiated. METHODS From 1984 until 1990, 82 eligible infants <1 year of age were entered on a Pediatric Oncology Group (POG) protocol 8493 for infant ALL. Compared to older patients, infants at diagnosis had more overt CNS leukemia (26%), higher initial WBC count (56% >50,000/microl), and a higher likelihood of CD-10 (CALLA) negative lymphoblasts (55%). A translocation involving chromosome 11 at band q23 was detected in 27 of 64 cytogenetically informative cases. Treatment was based upon two institutional pilot studies utilizing chemotherapy doses based upon body weight. Important components included remission induction with cyclophosphamide (Ctx), vincristine (Vcr), cytosine arabinoside (Ara-C), and prednisone (Pred) (COAP); consolidation therapy with teniposide (VM-26) and Ara-C; and continuation therapy with alternating pulses of COAP with VM-26/Ara-C separated by a methotrexate (Mtx) and 6-mercaptopurine (6-MP) backbone plus CNS therapy consisting of standard triple intrathecal therapy (TIT) (Mtx/hydrocortisone/Ara-C), which avoided the use of radiotherapy in this population. RESULTS Seventy-six infants achieved a complete remission (93%). Fifty patients have relapsed: 35 isolated marrow relapses, five isolated CNS relapses, eight combined marrow and CNS relapses, and two other relapses. Actuarial event-free survival was 28% (SE = 5%) at 4 years. Infants >274 days (9 months) at diagnosis had a better outcome than those <274 days. CONCLUSIONS This study represents a modest outcome improvement in comparison to previous experience with ALL for infants treated on POG trials. More effective therapy is still needed for infants with ALL.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D054198 Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. Leukemia, Lymphoblastic,Leukemia, Lymphoid, Acute,Lymphoblastic Leukemia,Lymphoblastic Lymphoma,Lymphocytic Leukemia, Acute,Lymphoma, Lymphoblastic,ALL, Childhood,Acute Lymphoid Leukemia,Leukemia, Acute Lymphoblastic,Leukemia, Lymphoblastic, Acute,Leukemia, Lymphoblastic, Acute, L1,Leukemia, Lymphoblastic, Acute, L2,Leukemia, Lymphoblastic, Acute, Philadelphia-Positive,Leukemia, Lymphocytic, Acute,Leukemia, Lymphocytic, Acute, L1,Leukemia, Lymphocytic, Acute, L2,Lymphoblastic Leukemia, Acute,Lymphoblastic Leukemia, Acute, Adult,Lymphoblastic Leukemia, Acute, Childhood,Lymphoblastic Leukemia, Acute, L1,Lymphoblastic Leukemia, Acute, L2,Lymphocytic Leukemia, L1,Lymphocytic Leukemia, L2,Acute Lymphoblastic Leukemia,Acute Lymphocytic Leukemia,Childhood ALL,L1 Lymphocytic Leukemia,L2 Lymphocytic Leukemia,Leukemia, Acute Lymphocytic,Leukemia, Acute Lymphoid,Leukemia, L1 Lymphocytic,Leukemia, L2 Lymphocytic,Lymphoid Leukemia, Acute,Precursor Cell Lymphoblastic Leukemia Lymphoma

Related Publications

L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
[Acute lymphoblastic leukemia in infants--results of treatment according to infant leukemia protocol--POG 8493].
January 1993, Acta haematologica Polonica,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Presenting characteristics of trisomy 8 as the primary cytogenetic abnormality associated with childhood acute lymphoblastic leukemia. A Pediatric Oncology Group (POG) Study (8600/8493).
July 1994, Cancer genetics and cytogenetics,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Pediatric Oncology Group (POG).
January 1996, Journal of the National Cancer Institute. Monographs,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9).
October 2013, Journal of pediatric hematology/oncology,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study (POG 8764).
January 2013, Journal of pediatric hematology/oncology,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study.
July 1994, Blood,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia.
September 2023, Pediatric blood & cancer,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
May 2021, Leukemia,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Infant Acute Lymphoblastic Leukemia-New Therapeutic Opportunities.
March 2024, International journal of molecular sciences,
L S Frankel, and J Ochs, and J J Shuster, and R Dubowy, and W P Bowman, and M Hockenberry-Eaton, and M Borowitz, and A J Carroll, and C P Steuber, and D J Pullen
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
February 2007, Blood,
Copied contents to your clipboard!